Our 2017

Our 2017

2017 has been a fantastic year for us at ARC Capital. We have reached new highs in our business, expanding our international reach to get closer to our customers.

International footprint:

-Mexico Office: Opened to better serve our Latin American clients; providing funding opportunities for middle sized companies through public or private markets. Serving as a critical geographic intersection between South and North America

-Sao Paulo Office: To focus on Brazilian clients with a special focus in F&B and Utilities sectors.

-Wuhan Office: Serving companies in central China

-Beijing Office: Focused on serving SOE/Large Corporate clients looking for investment opportunities overseas

-Singapore Office: Assisting clients in its dealings with Thailand, Indonesia and the entire region

– Collaboration agreements with other Boutique investment banks in Emerging Economies; increasing our international deal pipeline.

Increased service offering

– Launch of our Fund vehicle for China middle market companies.

– Launch of our Investor Relations business unit, supporting listed companies in getting coverage for Wall Street research analysts, increase institutional ownership and set up of roadshows to entice potential investors.

These reached milestones strengthen our presence and focus in the Emerging Markets, especially those in APAC and Latin America. Our vision is to become the leading middle markets investment bank in China and Latin America and we are now one step further to make it a reality.

Looking into the future, we are working on global expansion, grow our SPAC and Private Equity initiatives and solidify our Private Wealth Management offering. Stay tuned for more exciting news and iniitiatives! And remember that our mission is enable middle market companies realize their full potential using the power of finance!

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission